Nathan J. Dowden - Oct 25, 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
Chief Operating Officer
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Stock symbol
TRDA
Transactions as of
Oct 25, 2022
Transactions value $
-$194,191
Form type
4
Date filed
10/27/2022, 06:48 PM
Previous filing
Oct 24, 2022
Next filing
Nov 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Sale -$61K -3.03K -5.35% $20.10 53.7K Oct 25, 2022 Direct F1, F2
transaction TRDA Common Stock Sale -$114K -5.41K -10.08% $20.97 48.3K Oct 25, 2022 Direct F1, F3
transaction TRDA Common Stock Sale -$19.7K -900 -1.86% $21.85 47.4K Oct 25, 2022 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.51 to $20.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 to $21.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.66 to $22.14 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.